Bernard Iung1, Cédric Laouénan2, Dominique Himbert3, Hélène Eltchaninoff4, Karine Chevreul5, Patrick Donzeau-Gouge6, Jean Fajadet7, Pascal Leprince8, Alain Leguerrier9, Michel Lièvre10, Alain Prat11, Emmanuel Teiger12, Marc Laskar13, Alec Vahanian1, Martine Gilard14. 1. Cardiology Department, AP-HP, Hôpital Bichat Claude Bernard, Paris, France University Paris Diderot, Sorbonne Paris Cité, Paris, France. 2. University Paris Diderot, Sorbonne Paris Cité, Paris, France Biostatistic Department, AP-HP, Bichat Hospital, Paris, France. 3. Cardiology Department, AP-HP, Hôpital Bichat Claude Bernard, Paris, France. 4. Cardiology Department, Hôpital Charles Nicolle, University of Rouen, INSERM Unité 1096, Rouen, France. 5. URC Eco and UPEC EA 4393, AP-HP, Paris, France; 6. Institut Jacques Cartier, Massy, France. 7. Clinique Pasteur, Toulouse, France. 8. Cardiac Surgery Department, AP-HP, Hôpital Pitié-Salpetrière, Paris, France. 9. Cardiac Surgery Department, CHU Pontchaillou, Rennes, France. 10. Université Lyon 1, Lyon, France. 11. Cardiac Surgery Department, Hôpital Cardiologique, CHU, Lille, France. 12. Cardiology Department, AP-HP, Hôpital Henri Mondor, Créteil, France. 13. Cardiovascular Surgery Department, Hôpital Dupuytren, CHU, Limoges, France. 14. Cardiology Department, Hôpital de la Cavale Blanche, CHU, Brest, France.
Abstract
OBJECTIVE: Decision making for intervention in symptomatic aortic stenosis should balance the risks of surgery and of transcatheter aortic valve implantation (TAVI). We identified the factors associated with early mortality after TAVI and aimed to develop and validate a simple risk score. METHODS: A population of 3833 consecutive patients was randomly split into two cohorts comprising 2552 and 1281 patients, used respectively to develop and validate a scoring system predicting 30-day or in-hospital mortality. RESULTS: TAVI was performed using the Edwards Sapien prosthesis in 2551 (66.8%) patients and the Medtronic Corevalve in 1270 (33.2%). Approach was transfemoral in 2801 (73.4%) patients, transapical in 678 (17.8%), subclavian in 219 (5.7%) and other in 117 (3.1%). Early mortality was 10.0% (382 patients). A multivariate logistic model identified the following predictive factors of early mortality: age ≥90 years, body mass index <30 Kg/m(2), New York Heart Association class IV, pulmonary hypertension, critical haemodynamic state, ≥2 pulmonary oedemas during the last year, respiratory insufficiency, dialysis and transapical or other (transaortic and transcarotid) approaches. A 21-point predictive score was derived. C-index was 0.67 for the score in the development cohort and 0.59 in the validation cohort. There was a good concordance between predicted and observed 30-day mortality rates in the development and validation cohorts. CONCLUSIONS: Early mortality after TAVI is mainly related to age, the severity of symptoms, comorbidities and transapical approach. A simple score can be used to predict early mortality after TAVI. The moderate discrimination is however a limitation for the accurate identification of high-risk patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: Decision making for intervention in symptomatic aortic stenosis should balance the risks of surgery and of transcatheter aortic valve implantation (TAVI). We identified the factors associated with early mortality after TAVI and aimed to develop and validate a simple risk score. METHODS: A population of 3833 consecutive patients was randomly split into two cohorts comprising 2552 and 1281 patients, used respectively to develop and validate a scoring system predicting 30-day or in-hospital mortality. RESULTS: TAVI was performed using the Edwards Sapien prosthesis in 2551 (66.8%) patients and the Medtronic Corevalve in 1270 (33.2%). Approach was transfemoral in 2801 (73.4%) patients, transapical in 678 (17.8%), subclavian in 219 (5.7%) and other in 117 (3.1%). Early mortality was 10.0% (382 patients). A multivariate logistic model identified the following predictive factors of early mortality: age ≥90 years, body mass index <30 Kg/m(2), New York Heart Association class IV, pulmonary hypertension, critical haemodynamic state, ≥2 pulmonary oedemas during the last year, respiratory insufficiency, dialysis and transapical or other (transaortic and transcarotid) approaches. A 21-point predictive score was derived. C-index was 0.67 for the score in the development cohort and 0.59 in the validation cohort. There was a good concordance between predicted and observed 30-day mortality rates in the development and validation cohorts. CONCLUSIONS: Early mortality after TAVI is mainly related to age, the severity of symptoms, comorbidities and transapical approach. A simple score can be used to predict early mortality after TAVI. The moderate discrimination is however a limitation for the accurate identification of high-risk patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Harun Kundi; Linda R Valsdottir; Jeffrey J Popma; David J Cohen; Jordan B Strom; Duane S Pinto; Changyu Shen; Robert W Yeh Journal: Circ Cardiovasc Qual Outcomes Date: 2018-10
Authors: Didrik Kjønås; Gry Dahle; Henrik Schirmer; Siri Malm; Jo Eidet; Lars Aaberge; Terje Steigen; Svend Aakhus; Rolf Busund; Assami Rösner Journal: Health Sci Rep Date: 2021-05-06